Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC. Xu W, et al. Among authors: jeng ek. Cancer Res. 2013 May 15;73(10):3075-86. doi: 10.1158/0008-5472.CAN-12-2357. Epub 2013 May 3. Cancer Res. 2013. PMID: 23644531 Free PMC article.
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell BA, Keppel CR, Shah K, Hess B, Romee R, Piwnica-Worms DR, Cashen AF, Bartlett NL, Wong HC, Fehniger TA. Rosario M, et al. Among authors: jeng ek. Clin Cancer Res. 2016 Feb 1;22(3):596-608. doi: 10.1158/1078-0432.CCR-15-1419. Epub 2015 Sep 30. Clin Cancer Res. 2016. PMID: 26423796 Free PMC article.
IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas.
Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, Schlom J, Hodge JW. Kim PS, et al. Among authors: jeng ek. Oncotarget. 2016 Mar 29;7(13):16130-45. doi: 10.18632/oncotarget.7470. Oncotarget. 2016. PMID: 26910920 Free PMC article.
IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.
Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Tesone AJ, Perales-Puchalt A, Nguyen JM, Sarmin F, Sheen MR, Jeng EK, Tchou J, Wong HC, Fiering SN, Conejo-Garcia JR. Allegrezza MJ, et al. Among authors: jeng ek. Cancer Res. 2016 May 1;76(9):2561-72. doi: 10.1158/0008-5472.CAN-15-2808. Epub 2016 Mar 15. Cancer Res. 2016. PMID: 26980764 Free PMC article.
31 results